2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

Radionuclide-Drug Conjugates (RDCs)

" in MedChemExpress (MCE) Product Catalog:

49

Inhibitors & Agonists

40

Peptides

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2218
    Anditixafortide

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    Anditixafortide (Pentixather) is an endoradiotherapeutic vector. Anditixafortide is a CXCR4-targeting peptide derivative . Anditixafortide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Anditixafortide
  • HY-106033
    Edotreotide

    DOTATOC; SDZ-SMT 487; SMT 487

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Edotreotide is a somatostatin analogue. Edotreotide bound to various radionuclides, has the potential for the research and diagnosis of certain types of cancer . Edotreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Edotreotide
  • HY-106244A
    DOTATATE acetate
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE (acetate) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE acetate
  • HY-106244
    DOTATATE
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTATATE is a DOTA-conjugated peptide. DOTATATE can be labelled with radionuclides for positron emission tomography (PET) imaging and peptide receptor radionuclide research (PRRT) . DOTATATE can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTATATE
  • HY-P10232
    Hynic-toc

    HYNIC-Tyr3-octreotide

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    Hynic-toc (HYNIC-Tyr3-octreotide), a octreotide derivative, can be conjugated with radioactive element for tumor imaging . Hynic-toc can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Hynic-toc
  • HY-P10758
    Alkyne-βAG-TOCA

    		Somatostatin Receptor Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    Alkyne-βAG-TOCA, an octreotide derivative, targets somatostatin receptor type 2 (SST2) . Alkyne-βAG-TOCA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Alkyne-βAG-TOCA
  • HY-P10292
    NOTA-Pep-1L

    		Radionuclide-Drug Conjugates (RDCs) Interleukin Related Cancer
    NOTA-Pep-1L specifically targets the IL13RA2 receptor for tumor imaging . NOTA-Pep-1L can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-Pep-1L
  • HY-P5053
    Galacto-RGD

    		Radionuclide-Drug Conjugates (RDCs) Integrin Cancer
    Galacto-RGD is an RGD analogue that can be coupled with the radioactive isotope 18F and used as an integrin α?β? selective tracer . Galacto-RGD can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Galacto-RGD
  • HY-P10012
    Pendetide

    GYK-DTPA

    		 Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cancer
    Pendetide is a chelating agent, can be conjugated with Indium (111In) Capromab for further diagnostic use. Capromab pendetide is a FDA-approved imaging agent for the detection of soft tissue metastases in prostate carcinoma . Pendetide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pendetide
  • HY-P10273
    DOTA-Octreotide

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Cancer
    DOTA-Octreotide is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide is used for research of cancer, through combination with radioactive elements. DOTA-Octreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Octreotide
  • HY-153549
    Pentixafor

    		Radionuclide-Drug Conjugates (RDCs) CXCR Others
    Pentixafor is a peptide that targets CXCR4. Pentixafor is capable of being labelled with 68Gallium ( 68Ga) for positron emission tomography (PET) imaging . Pentixafor can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Pentixafor
  • HY-P10273A
    DOTA-Octreotide TFA

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Cancer
    DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-Octreotide TFA
  • HY-153550
    PSMA-1007

    		Radionuclide-Drug Conjugates (RDCs) PSMA Others
    PSMA-1007 is a prostate-specific membrane antigen (PSMA) ligand. 18F-labeled PSMA-1007 can be used as a PET tracer for prostate cancer imaging . PSMA-1007 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-1007
  • HY-P10741
    DOTA-EB-TATE

    		Radionuclide-Drug Conjugates (RDCs) Peptide-Drug Conjugates (PDCs) Somatostatin Receptor Cancer
    DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity. DOTA-EB-TATE can also be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-EB-TATE
  • HY-P10239
    Tyr3-Octreotate

    		Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate is a somatostatin analog. Tyr3-Octreotate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    Tyr3-Octreotate
  • HY-P2112
    DOTA-NOC

    DOTA-Nal3-octreotide

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Others
    DOTA-NOC (DOTA-Nal3-octreotide) is a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5. DOTA-NOC can be used for labeling with various radiometals, and development of radiopeptide imaging . DOTA-NOC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-NOC
  • HY-P10239A
    Tyr3-Octreotate acetate

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    Tyr3-Octreotate acetate is a somatostatin analog. Tyr3-Octreotate acetate exhibits high uptake into tumor, that is capable to be labeled with radioactive metal and thus exhibits antitumor efficacy. Tyr3-Octreotate acetate can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    Tyr3-Octreotate acetate
  • HY-P10220
    NOTA-COG1410

    		Radionuclide-Drug Conjugates (RDCs) Biochemical Assay Reagents Others
    NOTA-COG1410 forms triggering receptor expressed on myeloid cells 2 (TREM2) targeting radioligand for discovery and diagnosis of digestive system tumors through positron emission tomography/computed tomography . NOTA-COG1410 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-COG1410
  • HY-158266
    DOTA-PSMA-EB-01

    LNC1003

    		 Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC50= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of 177Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-PSMA-EB-01
  • HY-P10307
    DOTA-ubiquicidin (29–41)

    		Radionuclide-Drug Conjugates (RDCs) Bacterial Infection
    DOTA-ubiquicidin (29-41), an antimicrobial peptide fragment derivative, can be used for synthesis of [ 68Ga]Ga-DOTA-Ubiquicidin29-41 and then used for imaging of infectious processes using PET/CT . DOTA-ubiquicidin (29–41) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-ubiquicidin (29–41)
  • HY-P5128
    DOTA-JR11

    Satoreotide tetraxetan

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research . DOTA-JR11 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-JR11
  • HY-P5362
    NODAGA-LM3

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    NODAGA-LM3
  • HY-114133
    Depreotide

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    Depreotide is a nove tumor tarcer, can be complexed with technetium-99m ( 99mTc-depreotide) for optimal imaging properties. 99mTc-depreotide somatostain receptor imaging has been playing an important role in medical diagnosis research . Depreotide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Depreotide
  • HY-164725
    FAPI-mFS

    		Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    FAPI-mFS
  • HY-P5297
    DOTA-CXCR4-L

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    DOTA-CXCR4-L
  • HY-P10369
    Betiatide

    		Biochemical Assay Reagents Radionuclide-Drug Conjugates (RDCs) Cardiovascular Disease Inflammation/Immunology
    Betiatide, as a chelating agent for Technetium-99m ( 99mTc), is used to prepare 99mTc-MAG3 (mercaptoacetyltriglycine), a radiopharmaceutical for renal function imaging. Betiatide is used for the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstructions, and calculi . Betiatide can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    Betiatide
  • HY-P5362A
    NODAGA-LM3 TFA

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    NODAGA-LM3 TFA can be labeled by 68Ga for PET imaging. 68Ga-NODAGA-LM3 TFA is a SSTR2 antagonist, and can be used for imaging of SSTR positive paragangliomas. NODAGA-LM3 TFA can be labeled with [68Ga] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .
    NODAGA-LM3 TFA
  • HY-159768A
    DOTAGA.Glu.(FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    DOTAGA.Glu.(FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .
    DOTAGA.Glu.(FAPi)2
  • HY-159767A
    (S)-DOTAGA.(SA.FAPi)2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    (S)-DOTAGA.(SA.FAPi)2 is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging .
    (S)-DOTAGA.(SA.FAPi)2
  • HY-D2363
    DOTA.SA.FAPi TFA

    		FAP Radionuclide-Drug Conjugates (RDCs) Prolyl Endopeptidase (PREP) Cancer
    DOTA.SA.FAPi TFA inhibits fibroblast activation protein (FAP) with an IC50 of 0.9 nM. DOTA.SA.FAPi TFA targets protease PREP with an IC50 of 5.4 μM. DOTA.SA.FAPi TFA can be used a PET tracer, when labeled with 68Ga, and used for research about cancer . DOTA.SA.FAPi (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA.SA.FAPi TFA
  • HY-P10743
    BQ7876

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7876
  • HY-164588
    NH2-PEG4-NODA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-NODA-GA is a NODA-type metal chelator that can bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-NODA-GA
  • HY-P5018
    NOTA-AE105

    		Radionuclide-Drug Conjugates (RDCs) Ser/Thr Protease Cancer
    NOTA-AE105 is an PET ligand of urokinase-type plasminogen activator receptor (uPAR), which can be radiolabeled by 64Cu and 68Ga. 68Ga-NOTA-AE105 and 64Cu-NOTA-AE105 shows high image contrast, resulting in clear tumor delineation . NOTA-AE105 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    NOTA-AE105
  • HY-P10444
    DOTA Conjugated JM#21 derivative 7

    		Radionuclide-Drug Conjugates (RDCs) CXCR Cancer
    DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA Conjugated JM#21 derivative 7
  • HY-159770A
    (S)-EB-FAPI-B2

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .
    (S)-EB-FAPI-B2
  • HY-122939
    MAIPGG

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    MAIPGG is a bifunctional chelator and an intermediate in the synthesis of radionuclide drug conjugates (RDCs). MAIPGG can be for the radiolabeling of a variety of monoclonal antibodies with 99mTc or 186Re, which then can be used for radioimmunodetection and radioimmunotherapy of cancer .
    MAIPGG
  • HY-P5290
    HYNIC-PSMA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-PSMA is a ligand for molecular imaging of tumors. Hynic-psma consists of two components: HYNIC (6-hydrazinonicotinamide) and PSMA (Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules, such as 188Re-HYNIC-PSMA. PSMA is a membrane antigen that is specifically expressed on the surface of prostate cancer cells. HYNIC-PSMA can be used in prostate cancer research . HYNIC-PSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-PSMA
  • HY-132989
    Mal-Deferoxamine

    		Reactive Oxygen Species Apoptosis Autophagy HIF/HIF Prolyl-Hydroxylase Akt Radionuclide-Drug Conjugates (RDCs) Cancer
    Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. .
    Mal-Deferoxamine
  • HY-164569
    NH2 DOTA-GA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2 DOTA-GA is a DOTA-based metal chelator that can be used to prepare radionuclide drug conjugates (RDCs) whose carboxylic acid groups can complex metal ions. For example, NH2 DOTA-GA complexes Gd(III) ions.
    NH2 DOTA-GA
  • HY-P10781
    PSMA-D5

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    PSMA-D5 has a binding affinity for PSMA with Ki of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ 68Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as 177Lu and 225Ac. PSMA-D5 ([ 68Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    PSMA-D5
  • HY-P10761
    DPI-4452

    		Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase Cancer
    DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and study. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130?nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models . DPI-4452 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DPI-4452
  • HY-P5292
    HYNIC-iPSMA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA has excellent specificity and sensitivity . HYNIC-iPSMA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA
  • HY-W755033
    NH2-PEG4-DOTA

    		Radionuclide-Drug Conjugates (RDCs) Cancer
    NH2-PEG4-DOTA is a bifunctional, DOTA-type metal chelator. NH2-PEG4-DOTA can be conjugated with Dextran for quantitative analysis in the presence of a highly luminescent complex. NH2-PEG4-DOTA can also bind to radionuclides to prepare radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy.
    NH2-PEG4-DOTA
  • HY-P5292A
    HYNIC-iPSMA TFA

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    HYNIC-iPSMA TFA is a ligand for molecular imaging of tumors. Hynic-ipsma consists of two components: HYNIC (6-hydrazinonicotinamide) and iPSMA (Inhibitor of Prostate-Specific Membrane Antigen). HYNIC is a compound used to attach radioactive isotopes to targeted molecules. iPSMA is a specific inhibitor used to inhibit prostate-specific membrane antigen (PSMA). 68GA-labeled iPSMA has been used to detect prostate cancer by PET imaging. The further 99mTc-EDDA/HYNIC-iPSMA TFA has excellent specificity and sensitivity . HYNIC-iPSMA TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    HYNIC-iPSMA TFA
  • HY-P10744
    BQ7859

    		Radionuclide-Drug Conjugates (RDCs) PSMA Cancer
    BQ7859 is a probe targeting PSMA that contains a NOTA chelator and demonstrates excellent imaging performance. BQ7859 can be labeled with various radionuclides, such as 68Ga, 18F, 55Co, and 111In. In a mouse prostate cancer xenograft model, BQ7859 (labeled with 111In) efficiently accumulates in tumor regions in a PSMA-dependent manner and provides high-contrast tumor imaging. BQ7859 shows potential for research in prostate cancer imaging, particularly in positron emission tomography (PET) and single-photon emission computed tomography (SPECT) . BQ7859 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    BQ7859
  • HY-P10446
    TAT-PiET-PROTAC

    		Radionuclide-Drug Conjugates (RDCs) Epigenetic Reader Domain Cancer
    TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445). TAT-PiET is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can disrupt the interaction between the breast cancer oncogene BRD4/JMJD6 and inhibit the growth of breast cancer cells. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells and is a potential inhibitor of breast cancer . TAT-PiET-PROTAC can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    TAT-PiET-PROTAC
  • HY-P5126
    DOTA-LM3
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3
  • HY-P5126A
    DOTA-LM3 TFA
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).
    DOTA-LM3 TFA
  • HY-W087187
    DOTAGA-anhydride

    		Radionuclide-Drug Conjugates (RDCs) EGFR Cancer
    DOTAGA-anhydride is a DOTA-based metal chelator that can bind to radionuclides and is used to prepare radionuclide drug conjugates (RDCs). DOTAGA-anhydride can be used to label monoclonal antibodies (mAbs) such as trastuzumab (targeting HER2/neu receptor with an affinity of 5.5 nM) under mild conditions (PBS pH 7.4, 25 °C, 30 minutes) after chelation with indium-111. [111In-DOTAGA]-trastuzumab showed a tumor uptake of 65% ID/g in mice bearing breast cancer BT-474 xenografts 72 hours after injection, which is valuable for SPECT/CT imaging and biodistribution studies.
    DOTAGA-anhydride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: